Pegfilgrastim injection bulk supplier for pharma manufacturers

Pegfilgrastim Injection 6 mg per single-use syringe Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 6 mg per single-use syringe

Reference Brands: Neulasta, Pelgraz(US), Pegex (Inida)

Pegfilgrastim stimulates the production of neutrophils by binding to G-CSF receptors, reducing the risk of infection during chemotherapy-induced neutropenia. Its benefits include rapid neutrophil recovery, decreased infection rates, fewer hospitalizations, and improved treatment safety, enabling patients to continue chemotherapy effectively with lower complication risks.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Pegfilgrastim injection, marketed as Neulasta and biosimilars like Pelgraz, is approved in the US by the FDA and in the EU via EMA for preventing chemotherapy-induced neutropenia. Regulatory approval requires a comprehensive dossier including biosimilarity data, clinical efficacy, safety, manufacturing quality, and pharmacovigilance plans. In the US, FDA review involves detailed assessment of the biosimilar complex, while the EMA ensures compliance with regional standards. For guidance on dossier preparation, regulatory pathways, and successful market access strategies, visit PharmaTradz. Ensuring compliance with regional regulations is essential for the safe, effective, and timely approval of pegfilgrastim injection worldwide, supporting patient safety during cancer chemotherapy.

Pegfilgrastim Injection — third party manufacturing & bulk supply

Pegfilgrastim Injection 6 mg per single-use syringe is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Pegfilgrastim Injection is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Pegfilgrastim Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Pegfilgrastim Injection →

Back to Listing

Frequently Asked Questions

Pegfilgrastim Injection is used to reduce the risk of infection in patients receiving chemotherapy by stimulating the production of white blood cells, particularly neutrophils.

Pegfilgrastim is a pegylated recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the bone marrow to produce more neutrophils.

Common trade names include Neulasta, Ziextenzo, Udenyca, Fulphila, Nyvepria, Pelgraz, Pelmeg, and Pegex.

The original brand Neulasta was developed and marketed by the pharmaceutical company Amgen, while several pharmaceutical companies manufacture biosimilar pegfilgrastim products worldwide.

The generic name is Pegfilgrastim.

Common brand names include Neulasta, Ziextenzo, Udenyca, Fulphila, Nyvepria, Pelgraz, Pelmeg, and Pegex.

Pegfilgrastim Injection is manufactured in several countries including the United States, Germany, India, and other regions by different pharmaceutical manufacturers.